What is clinical trial NCT05203172 studying?

NCT05203172 is a Phase 4 clinical trial evaluating Binimetinib for Solid Tumors. The trial is sponsored by Pfizer and is currently recruiting.

What phase is the NCT05203172 clinical trial?

NCT05203172 is a Phase 4 clinical trial. This trial phase varies in design. Check ClinicalTrials.gov for full protocol details.

Is NCT05203172 still recruiting participants?

The current enrollment status of NCT05203172 is: Recruiting. The trial is actively enrolling — check ClinicalTrials.gov for eligibility criteria.

Who is the sponsor of clinical trial NCT05203172?

NCT05203172 is sponsored by Pfizer (PFE). BiotechSign currently grades the sponsor a C (52/100) based on its composite pipeline strength and catalyst outlook.

Home›Trial›NCT05203172

NCT05203172Phase 4Recruiting

The FLOTILLA Study: Providing Continued Access to The Study Medicines Encorafenib and Binimetinib for Participants in Prior Clinical Trials

Study Summary

The purpose of this clinical trial (called the FLOTILLA study) is to give continued access to the study medicines, as well as safety follow-up, for participants in prior clinical trials of encorafenib and/or binimetinib. All participants who took part in earlier encorafenib and/or binimetinib studies may participate in the FLOTILLA study if they are still benefiting from the use of the study medicines. This will be determined by the study doctor. People may not participate in the FLOTILLA study if they were not enrolled in a prior study of encorafenib or binimetinib. Participants who had enrolled but had stopped receiving the study treatment in a prior study cannot be enrolled in this study. Participants in the FLOTILLA study will receive study treatment at the same dose and frequency as in their prior study, for up to about 5 years.

Conditions

Solid Tumors

Interventions / Drugs

Binimetinib Encorafenib Vemurafenib Ribociclib Cetuximab Pembrolizumab Nivolumab 5-Fluorouracil Leucovorin Oxaliplatin Irinotecan Capecitabine Bevacizumab

View on ClinicalTrials.gov ↗

Sponsor

Study Details

Enrollment210 participants

Primary Completion2029-07-31

Lead SponsorPfizer

Data Retrieved2026-10-14

What This Trial Means for Biotech Investors

Trial Phase Context

This trial phase represents an early or specialized stage of clinical development.

Status & Expected Data

Currently recruiting: the trial is enrolling patients. A data readout is not expected until after enrollment closes and the follow-up period is complete.

Primary completion: 2029-07-31

Enrolled: 210 participants

Sponsor Catalyst Profile

Pfizer Inc (PFE) is the sponsoring company for this trial. BiotechSign currently grades this company C (52/100) based on composite catalyst signals across its full pipeline. This trial is one data point in that overall catalyst picture.

PFE Full Pipeline →All Companies →

Other Trials from Pfizer Inc

NCT05805826To Understand the Safety and Effects of a C. Difficile Vaccine With New Adds-Ons…(PHASE1/PHASE2)NCT07215078Study About Whether Atirmociclib/PF-07220060 Proportionally Increases Exposure a…(PHASE1)NCT07363694A Study to Learn About the Study Medicine Called PF-07275315 in People With Mode…(PHASE2/PHASE3)NCT05571839A Study of PF-08046049/SGN-BB228 in Advanced Melanoma and Other Solid Tumors(PHASE1)NCT07222800Symbiotic-GI-03: A Study to Learn About the Study Medicine Called PF-08634404 in…(PHASE3)

Not financial advice. BiotechSign data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.